List of Tables
Table 1. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Trends
Table 2. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Drivers & Opportunity
Table 3. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Challenges
Table 4. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Restraints
Table 5. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Market Share by Company (2019-2024)
Table 7. Key Companies Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Manufacturing Base Distribution and Headquarters
Table 8. Key Companies Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Product Type
Table 9. Key Companies Time to Begin Mass Production of Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics
Table 10. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics as of 2023)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 14. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Type (2019-2024) & (US$ Million)
Table 15. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Type (2025-2030) & (US$ Million)
Table 16. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Market Share in Value by Type (2019-2024) & (%)
Table 17. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Market Share in Value by Type (2025-2030) & (%)
Table 18. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 19. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Application (2019-2024) & (US$ Million)
Table 20. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Application (2025-2030) & (US$ Million)
Table 21. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Market Share in Value by Application (2019-2024) & (%)
Table 22. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Market Share in Value by Application (2025-2030) & (%)
Table 23. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 24. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Region (2019-2024) & (US$ Million)
Table 25. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Region (2025-2030) & (US$ Million)
Table 26. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Region (2019-2024) & (%)
Table 27. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Region (2025-2030) & (%)
Table 28. Key Countries/Regions Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 29. Key Countries/Regions Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value, (2019-2024) & (US$ Million)
Table 30. Key Countries/Regions Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value, (2025-2030) & (US$ Million)
Table 31. Astellas Inc. Basic Information List
Table 32. Astellas Inc. Description and Business Overview
Table 33. Astellas Inc. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Products, Services and Solutions
Table 34. Revenue (US$ Million) in Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Business of Astellas Inc. (2019-2024)
Table 35. Astellas Inc. Recent Developments
Table 36. Johnson & Johnson Basic Information List
Table 37. Johnson & Johnson Description and Business Overview
Table 38. Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Products, Services and Solutions
Table 39. Revenue (US$ Million) in Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Business of Johnson & Johnson (2019-2024)
Table 40. Johnson & Johnson Recent Developments
Table 41. Sanofi S.A Basic Information List
Table 42. Sanofi S.A Description and Business Overview
Table 43. Sanofi S.A Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Products, Services and Solutions
Table 44. Revenue (US$ Million) in Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Business of Sanofi S.A (2019-2024)
Table 45. Sanofi S.A Recent Developments
Table 46. Dendreon Corporation Basic Information List
Table 47. Dendreon Corporation Description and Business Overview
Table 48. Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Products, Services and Solutions
Table 49. Revenue (US$ Million) in Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Business of Dendreon Corporation (2019-2024)
Table 50. Dendreon Corporation Recent Developments
Table 51. Bayer AG Basic Information List
Table 52. Bayer AG Description and Business Overview
Table 53. Bayer AG Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Products, Services and Solutions
Table 54. Revenue (US$ Million) in Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Business of Bayer AG (2019-2024)
Table 55. Bayer AG Recent Developments
Table 56. Key Raw Materials Lists
Table 57. Raw Materials Key Suppliers Lists
Table 58. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Downstream Customers
Table 59. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Distributors List
Table 60. Research Programs/Design for This Report
Table 61. Key Data Information from Secondary Sources
Table 62. Key Data Information from Primary Sources
Table 63. Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Product Picture
Figure 2. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 4. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Report Years Considered
Figure 5. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Players Revenue Ranking (2023) & (US$ Million)
Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue in 2023
Figure 7. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 8. Oral Therapy Picture
Figure 9. Injectable Therapy Picture
Figure 10. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 11. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value Market Share by Type, 2023 & 2030
Figure 12. Product Picture of Hospitals & Clinics
Figure 13. Product Picture of Home Settings
Figure 14. Product Picture of Ambulatory Surgical Centers (ASCs)
Figure 15. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 16. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value Market Share by Application, 2023 & 2030
Figure 17. North America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 18. North America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Country (%), 2023 VS 2030
Figure 19. Europe Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 20. Europe Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Country (%), 2023 VS 2030
Figure 21. Asia Pacific Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 22. Asia Pacific Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Country (%), 2023 VS 2030
Figure 23. South America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 24. South America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Country (%), 2023 VS 2030
Figure 25. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 26. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Country (%), 2023 VS 2030
Figure 27. Key Countries/Regions Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value (%), (2019-2030)
Figure 28. United States Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 29. United States Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 30. United States Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 31. Europe Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 32. Europe Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 33. Europe Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 34. China Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 35. China Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 36. China Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 37. Japan Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 38. Japan Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 39. Japan Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 40. South Korea Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 41. South Korea Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 42. South Korea Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 43. Southeast Asia Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 44. Southeast Asia Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 45. Southeast Asia Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 46. India Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 47. India Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 48. India Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 49. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Industrial Chain
Figure 50. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Manufacturing Cost Structure
Figure 51. Channels of Distribution (Direct Sales, and Distribution)
Figure 52. Bottom-up and Top-down Approaches for This Report
Figure 53. Data Triangulation